10-K · February 27, 2026
Teleflex’s 2025 10-K frames the year as a strategic inflection: management completed the June 30, 2025 acquisition of BIOTRONIK’s Vascular Intervention business and on December 9, 2025 entered definitive agreements to…
Earnings analysis · 10-Q
TFX earnings analysis
Filed May 7, 2026 · Our reading of the company's report
The latest report
Teleflex's Q1 2026 earnings report highlights a significant revenue increase of 32.3% year-over-year, totaling $548.3 million, largely driven by the newly acquired VI Business. However, gross margins contracted to…
Read full summary
Teleflex's Q1 2026 earnings report highlights a significant revenue increase of 32.3% year-over-year, totaling $548.3 million, largely driven by the newly acquired VI Business. However, gross margins contracted to 56.1%, declining by 560 basis points, while the diluted EPS of $1.39 exceeded consensus estimates.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
Where revenue came from
The business segments reported by the company.
Shares of the segments disclosed in this filing, largest first.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $1.39
- Gross margin
- 56.1%
What stood out
-
Strong Revenue Growth
Q1 2026 revenue rose to $548.3 million, up 32.3% from $414.3 million in Q1 2025.
-
Adjusted EPS Outperforming
Diluted EPS for Q1 2026 stood at $1.39, above the estimated $1.22.
-
Segment Growth in EMEA and Asia
EMEA revenues up 77.5% to $146.7 million, driven by the VI Business acquisition.
-
Restructuring Gains Expected
The company anticipates annual pre-tax savings of $48M to $52M from its Strategic Divestitures restructuring plan.
-
Improvement in Cash Flow
Net cash from operations improved to $46.7 million, from $27.7 million in the same period last year.
-
Significant Cash Settlement Received
Teleflex received $25 million from a litigation settlement, bolstering financial resources.
What to watch
-
Increased Tariff Impact
Gross margin decreased by 560 bps to 56.1% due to adverse tariff effects and increased costs.
-
CEO Transition Uncertainty
Leadership changes may affect strategic direction and operational stability in the near term.
-
Activist Investor Pressure
Emerging activism from Irenic Capital could instigate strategic changes that disrupt current operations.
Management's outlook
Continued 14.40% to 15.40% revenue growth guidance for full-year 2026.
Earlier filings 4
10-Q · July 31, 2025
Teleflex reported quarterly net revenues of $780.9 million, up 4.2% year-over-year, while gross margin compressed 40 basis points to 55.2%. Management achieved cost reductions (SG&A down $35.5 million) and segment…
10-K · February 23, 2023
Teleflex's 10-K report for 2022 highlights a business focused on enhancing clinical benefits and reducing procedural costs through its robust portfolio of medical technology products. The company continues to invest in…
10-Q · July 28, 2022
Teleflex reported quarterly net revenues of $704.5M, down $9.0M or 1.3% versus the year-ago quarter, with gross profit of $388.8M (55.2% of sales, down 50 bps). Consolidated segment operating profit was $166.5M…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.